Cite
MLA Citation
A Diab et al.. “1245PDIntratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study.” Annals of oncology, vol. 29, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100095500578.0x000036